Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ralmitaront trial for negative symptoms in schizophrenia
jRCT2031200287Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ralmitaront in schizophrenia and schizoaffective disorder (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: BNSS total score. Started Apr 2021; status: completed.
02
Drugs
ralmitaront
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on jRCT2031200287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200287.